Hervé Farine

Serum <scp>IL</scp>‐5 and <scp>IL</scp>‐13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics

Ioana Agache, Daniel S. Strasser, Axel Klenk et al. · Allergy · 2016 · 67 citations

Impact of high‐altitude therapy on type‐2 immune responses in asthma patients

Tadech Boonpiyathad, Gertruda Capova, Hans‐Werner Duchna et al. · Allergy · 2019 · 42 citations · Full text

ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases

Laetitia Pouzol, Nadège Baumlin, Anna Sassi et al. · The FASEB Journal · 2021 · 36 citations · Full text

Immunology, Immune Regulation, Immunotherapy +19

Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients

Richard W.D. Welford, Hervé Farine, Michel A. Steiner et al. · Molecular Genetics and Metabolism Reports · 2022 · 22 citations · Full text

A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects

Martine Géhin, Daniel S. Strasser, Jochen Zisowsky et al. · The Journal of Clinical Pharmacology · 2015 · 18 citations

Medicinal Chemistry, Novel Crth2 Antagonist, Steady State +15